Söndag 22 December | 12:06:05 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2022-01-26 - Bokslutskommuniké 2021
2021-07-14 - Kvartalsrapport 2021-Q2
2021-06-30 - Årsstämma
2021-05-27 - X-dag ordinarie utdelning NATTO 0.00 NOK
2021-02-17 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-07-15 - Kvartalsrapport 2020-Q2
2020-06-22 - X-dag ordinarie utdelning NATTO 0.00 NOK
2020-06-19 - Årsstämma
2020-05-06 - Kvartalsrapport 2020-Q1
2020-02-19 - Bokslutskommuniké 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning NATTO 0.00 NOK
2019-05-29 - Årsstämma
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-13 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning NATTO 0.00 NOK
2018-05-30 - Årsstämma
2018-02-08 - Bokslutskommuniké 2017
2017-11-24 - Extra Bolagsstämma 2017
2017-08-16 - Kvartalsrapport 2017-Q2
2017-05-16 - X-dag ordinarie utdelning NATTO 0.00 NOK
2017-05-15 - Årsstämma
2017-05-15 - Kapitalmarknadsdag 2017
2017-05-15 - Kvartalsrapport 2017-Q1
2017-02-08 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-20 - Årsstämma
2016-05-20 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-11-25 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2014-11-26 - Kvartalsrapport 2014-Q3
2014-08-27 - Kvartalsrapport 2014-Q2
2014-05-27 - Kvartalsrapport 2014-Q1
2014-02-17 - Bokslutskommuniké 2013
2013-11-26 - Kvartalsrapport 2013-Q3
2013-08-27 - Kvartalsrapport 2013-Q2
2013-05-22 - Kvartalsrapport 2013-Q1
2013-02-28 - Bokslutskommuniké 2012
2012-11-15 - Kvartalsrapport 2012-Q3
2012-08-21 - Kvartalsrapport 2012-Q2
2012-05-16 - Kvartalsrapport 2012-Q1
2012-02-28 - Bokslutskommuniké 2011
2012-02-13 - Extra Bolagsstämma 2012
2011-11-17 - Kvartalsrapport 2011-Q3
2011-10-31 - Extra Bolagsstämma 2011
2011-08-18 - Kvartalsrapport 2011-Q2
2011-05-19 - Kvartalsrapport 2011-Q1
2011-02-25 - Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.
2021-06-09 17:00:00

Lille/Oslo, 9 June 2021

Reference is made to the stock exchange announcement earlier today, 9 June 2021, regarding  Compagnie des Levures Lesaffre's ("Lesaffre") announcement of a compulsory acquisition of all shares in NattoPharma ASA ("NattoPharma" or the "Company") not already owned by Lesaffre.

The Board of Directors of Lesaffre has, effective from close of trading on Oslo Børs today, 9 June 2021, resolved to carry out the compulsory acquisition of all remaining shares in NattoPharma not owned by Lesaffre, pursuant to the Norwegian Public Limited Liability Companies Act section 4-25 cf. the Norwegian Securities Trading Act section 6-22 (1). As a consequence, Lesaffre has assumed ownership of all shares in the Company.

The offered redemption price under the compulsory acquisition is NOK 35.00 per share, which corresponds to the offer price in the preceding mandatory offer and, according to the Norwegian Securities Trading Act section 6-22 (2), is the applicable redemption price in a subsequent compulsory acquisition. Lesaffre has deposited the total acquisition amount on a separate account with Nordea, in accordance with the Norwegian Public Limited Liability Companies Act section 4-25 (5).

A notice regarding the compulsory acquisition will be sent to all former shareholders subject to the compulsory transfer, whose addresses are known. In addition, the compulsory acquisition will be announced through the electronic notice service of the Norwegian Register of Business Enterprises (Nw. Brønnøysundregistrene) if required pursuant to applicable law.

As a consequence of the compulsory acquisition, Lesaffre will pursue a de-listing of the Company's shares from Euronext Expand. Separate stock exchange notices will be published regarding the timing for such delisting.

Oslo Børs is requested to suspend the Company's shares from trading without delay.

Rothschild is acting as financial adviser to Lesaffre and Nordea Bank Abp, filial i Norge, is acting as receiving agent. Advokatfirmaet Thommessen AS is acting as the Norwegian legal adviser, and Linklaters is acting as the French legal adviser, to Lesaffre.

For further information, please contact:

NattoPharma:

NattoPharma ASA
Att: Kjetil Ramsøy
Telephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com

Lesaffre:

Agence Wellcom
Att: Valérie Lassale/Chloe Bencivengo
Telephone: +33(0)1 46 34 60 60
Email: lesaffre@wellcom.fr